Clopidogrel + Prasugrel + Commercially-available Aspirin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Coronary Syndrome
Conditions
Acute Coronary Syndrome
Trial Timeline
Jun 1, 2008 → Apr 1, 2012
NCT ID
NCT00699998About Clopidogrel + Prasugrel + Commercially-available Aspirin
Clopidogrel + Prasugrel + Commercially-available Aspirin is a phase 3 stage product being developed by Daiichi Sankyo for Acute Coronary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00699998. Target conditions include Acute Coronary Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Acute Coronary Syndrome were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00699998 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Coronary Syndrome